http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108138171-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-163 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2016-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108138171-B |
| titleOfInvention | Preparation method of genetically modified T cells expressing chimeric antigen receptor |
| abstract | The present invention realizes the improvement of the gene introduction efficiency of the CAR therapy using the transposon method. The present invention provides a method for preparing a genetically modified T cell expressing a chimeric antigen receptor, comprising the following steps: (1) a step of preparing non-proliferative cells, wherein the non-proliferative cells are prepared by using anti-CD3 antibody and It is obtained by stimulating a cell population containing T cells with anti-CD28 antibody, and then performing a treatment to inactivate the proliferation ability; (2) Obtaining genetically modified T cells into which the target antigen-specific chimeric antigen receptor gene has been introduced by the transposon method The steps of cell; (3) mixing the non-proliferative cells prepared in step (1) and the genetically modified T cells obtained in step (2), and co-culturing the cells while stimulating with anti-CD3 antibody and anti-CD28 antibody. step; (4) the step of recovering the cultured cells. In addition, the present invention provides a method for preparing a genetically modified T cell expressing a chimeric antigen receptor, comprising the following steps: (i) a step of preparing a non-proliferative cell that retains a viral peptide antigen that retains a viral peptide Antigen non-proliferating cells are obtained by culturing in the presence of viral peptide antigens and treatment to inactivate proliferation after stimulation of a T cell-containing cell population with anti-CD3 and anti-CD28 antibodies; (ii) The step of obtaining genetically modified T cells into which the target antigen-specific chimeric antigen receptor gene has been introduced by the transposon method; (iii) combining the non-proliferating cells prepared in step (i) with the gene obtained in step (ii) The step of mixing and co-cultivating modified T cells; (iv) the step of recovering the cultured cells. |
| priorityDate | 2015-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 615.